Simeprevir - Medivir/Janssen R&D Ireland
Alternative Names: Galexos; JNJ-38733214-AAA; Olysio; R-494617; SMV; Sovriad; TMC-435; TMC-435350Latest Information Update: 05 Nov 2023
At a glance
- Originator Medivir AB
- Developer Alios BioPharma; Janssen Pharmaceutical KK; Janssen R&D Ireland; Medivir AB
- Class 3-ring heterocyclic compounds; Antivirals; Cyclopropanes; Quinolines; Small molecules; Sulfonamides; Thiazoles
- Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis C
Most Recent Events
- 19 Feb 2021 No development reported - Phase-II for Hepatitis C (Combination therapy) in Mauritius and Moldova (PO)
- 11 May 2018 Alios Biopharma completes a phase II trial in Hepatitis C in New Zealand, Moldova, Mauritius, United Kingdom (NCT02569710)
- 07 May 2018 Janssen completes a phase II trial in Hepatitis C (Combination therapy) in Japan (PO) (NCT02993250)